Addressing Common Talquetamab Misunderstandings
Panelists discuss how health care providers and patients should understand that talquetamab's unique adverse effects are temporary and resolve over time, even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.
EP: 1.Alan's Multiple Myeloma Journey: Facing a New Diagnosis
EP: 2.Connecting With Multiple Myeloma Support Groups and Online Resources
EP: 3.Alan's Treatment Course and Quality-of-Life Goals
EP: 4.Coordinated Health Care Teams and Caregiver Support
EP: 5.Extending Talquetamab Education Beyond the Hospital
EP: 6.Addressing Early Talquetamab Toxicity Concerns
EP: 7.Developing a System-Wide Protocol for Talquetamab Toxicity Management
EP: 8.Practical Tips for Managing Nail and Skin Changes While Receiving Talquetamab
EP: 9.Managing Taste Changes and Weight Loss During Talquetamab Treatment
EP: 10.Advice for the Patient Starting Treatment With Talquetamab
EP: 11.Advice for the Caregiver: Be a Patient Advocate
EP: 12.Addressing Common Talquetamab Misunderstandings
Patients on long-term talquetamab demonstrate that initial adverse effects resolve even with continued treatment, with patients regaining full taste function and returning to a normal quality of life while maintaining disease control. Samantha Shenoy, NP, MSN, emphasizes educating both patients and providers that toxicities improve over time rather than persist throughout treatment duration. This message counters misconceptions that might deter patients from considering this effective therapy option.
Provider education remains crucial as many health care professionals are new to bispecific antibody management and may not fully understand the temporary nature of GPRC5D-related toxicities. Educational initiatives aim to build confidence among providers in prescribing talquetamab by demonstrating that while initial adverse effects require attention, they resolve predictably. This education helps providers counsel patients appropriately about realistic expectations for treatment tolerance.
The discussion emphasizes removing stigma around talquetamab's unique adverse effect profile while highlighting its excellent efficacy in patients with heavily pretreated multiple myeloma. Alan Plisskin and Mary Kay Yamamoto’s positive experience after navigating initial challenges provides real-world evidence that patients can achieve excellent quality-of-life outcomes with proper preparation, support, and understanding of the treatment timeline. Their story illustrates that with the appropriate education and support systems; patients can successfully manage talquetamab therapy and achieve meaningful clinical benefits.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
